Yahoo
NasdaqCM - Nasdaq Real Time Price USD

GRI Bio, Inc. (GRI)

2.0800 +0.0500 (+2.48%)
As of 11:20:37 AM EDT. Market Open.
Chart Range Bar
Loading chart for GRI
  • Previous Close 2.0300
  • Open 2.0100
  • Bid 2.2200 x 100
  • Ask 2.3400 x 100
  • Day's Range 1.9700 - 2.0800
  • 52 Week Range 1.9700 - 80.3600
  • Volume 9,296
  • Avg. Volume 82,942
  • Market Cap (intraday) 3.006M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -121.8000
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 40.00

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

www.gribio.com

3

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: GRI

View More

Performance Overview: GRI

Trailing total returns as of 5/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GRI
69.92%
S&P 500 (^GSPC)
7.84%

1-Year Return

GRI
95.05%
S&P 500 (^GSPC)
23.90%

3-Year Return

GRI
100.00%
S&P 500 (^GSPC)
75.85%

5-Year Return

GRI
100.00%
S&P 500 (^GSPC)
78.84%

Earnings Trends: GRI

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -2M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-3M
-2M
-1M
0

Analyst Insights: GRI

View More

Analyst Price Targets

40.00
40.00 Average
2.0800 Current
40.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/11/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 1008 -> 40

Statistics: GRI

View More

Valuation Measures

Annual
As of 5/8/2026
  • Market Cap

    3.24M

  • Enterprise Value

    -4.91M

  • Trailing P/E

    0.01

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.54

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -88.82%

  • Return on Equity (ttm)

    -185.67%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.91M

  • Diluted EPS (ttm)

    -121.8000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.05M

  • Total Debt/Equity (mrq)

    0.55%

  • Levered Free Cash Flow (ttm)

    -7.61M

Compare To: GRI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: GRI

Fair Value

2.0800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: